Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges
Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks to buy according to Wall Street analysts.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 8,322,179 | $450,729,215 | -33% | 1.17% |
| 2. | AQR Capital Management Cliff Asness | 5,932,109 | $321,283,017 | +7% | 0.21% |
| 3. | Millennium Management Israel Englander | 2,627,210 | $142,289,694 | -8% | 0.06% |
| 4. | Renaissance Technologies Jim Simons | 1,893,571 | $102,555,805 | +5% | 0.14% |
| 5. | GLG Partners Noam Gottesman | 1,493,379 | $80,881,406 | +2% | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.31 | 1,786 | $105,927.66 | 14,173 | 2025-05-20 | Filing | |
| $64.92 | 273 | $17,723.16 | 32,700 | 2025-05-02 | Filing | |
| $71.52 | 1,295 | $92,618.40 | 16,955 | 2025-03-19 | Filing | |
| $71.28 | 7,034 | $501,355.38 | 87,655 | 2025-03-06 | Filing | |
| $68.38 | 1,344 | $91,902.72 | 13,105 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,046,050 | $1,194,014,041 | 0.02% | |
| 2. | 18,582,585 | $1,006,432,803 | 0.02% | |
| 3. | 15,229,287 | $824,818,238 | 0.63% | |
| 4. | 14,686,801 | $795,437,142 | 0.43% | |
| 5. | 8,764,599 | $474,690,682 | 0.02% |
News See All
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the cheap healthcare stocks to buy heading into 2026. As reported by TheFly, Leerink reduced the price target on BioMarin Pharmaceutical Inc.
12 Cheap Healthcare Stocks to Buy Heading into 2026
Since the pandemic, healthcare is one of the sectors that have remained in the spotlight even amid market twists.
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory
We came across a bullish thesis on BioMarin Pharmaceutical Inc. on Value investing subreddit by BearWithMeGM. In this article, we will summarize the bulls’ thesis on BMRN.
J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best stocks to buy with over 50% upside potential. BioMarin Pharmaceutical Inc.
10 Stocks to Buy With Over 50% Upside Potential
He stated that the market has begun to exhibit signs of increased speculation.
10 Best Beaten Down Growth Stocks to Buy According to Analysts
On October 27, Tejas Dessai, Director of Research at Global X ETFs, joined CNBC Television for an interview to discuss how the big tech earnings this week are expected to impact the broader stock market...
BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Stocks to Buy with Exponential Growth Heading into 2026.
13 Stocks to Buy with Exponential Growth Heading into 2026
As per Fidelity, the tax law that was passed over the summer is projected to reduce the effective corporate tax rate.
Hedge Fund Resource Center Billionaire Hedge Funds
